In a multicenter phase 1 study, patients with ND-AML with an IDH1 (N = 60) or IDH2 mutation (N = 93) received the respective IDHi at FDA-approved doses in combination with daunorubicin 60 mg/m2 administered D1-3 and cytarabine 200 mg/m2 administered D1-7 during induction, followed by up to four consolidation cycles of intermediate/high-dose cytarabine or one cycle of mitoxantrone/etoposide [65]. The gene discussed is IDH2; the disease is acute myeloid leukemia.